Last Updated: November 18, 2026

Details for Patent: 10,016,429

« Back to Dashboard


Which drugs does patent 10,016,429 protect, and when does it expire?

Patent 10,016,429 protects JAKAFI XR and JAKAFI and is included in two NDAs.

Protection for JAKAFI XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-nine patent family members in forty-one countries.

Summary for Patent: 10,016,429
Title:Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Abstract:The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s):James D. Rodgers, Hui-Yin Li
Assignee: Incyte Corp , Incyte Holdings Corp
Application Number:US15/164,518
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,016,429
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

US Patent 10,016,429: Itacitinib Phosphate Patent Scope, Expiration, Litigation and Generic Risk

US Patent 10,016,429 protects methods of treating allograft rejection and graft-versus-host disease with itacitinib phosphate, including its crystalline 1:1 phosphate salt and oral tablet formulations. The patent does not claim itacitinib broadly for every disease or every formulation. Its enforceable scope is concentrated on a defined stereoisomer, a phosphoric-acid salt, and two transplant-related indications.

The patent was assigned to Incyte Corporation and issued on July 10, 2018. The underlying compound is commonly identified as itacitinib, also known as INCB039110. Itacitinib has not obtained FDA approval, so the patent has no identified Orange Book listing, no approved-product regulatory exclusivity, and no conventional Paragraph IV litigation pathway tied to an approved NDA.

What compound does US Patent 10,016,429 protect?

The claimed compound is the R enantiomer of a pyrrolopyrimidine-pyrazole compound formulated as a phosphoric acid salt:

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt.

This compound corresponds to itacitinib phosphate. Itacitinib is a selective Janus kinase 1, or JAK1, inhibitor developed by Incyte for inflammatory, autoimmune and hematologic indications.

The claims define the product through several structural limitations:

Limitation Scope
Stereochemistry R configuration at the relevant chiral center
Core 7H-pyrrolo[2,3-d]pyrimidin-4-yl group linked through a pyrazole
Side chain Cyclopentyl-substituted propanenitrile
Salt Phosphoric acid salt
Solid state Crystalline salt in dependent claims
Stoichiometry 1:1 drug-to-phosphoric-acid salt in claims 5 and 12
Administration Therapeutically effective administration to a patient
Disease Allograft rejection or graft-versus-host disease
Formulation Pharmaceutical composition with a pharmaceutically acceptable carrier
Dosage form Oral composition and tablet in dependent claims

The patent therefore covers more than a chemical identity. It combines product definition with treatment indication and, in some claims, formulation and solid-state limitations.

What are the independent claims in US Patent 10,016,429?

Claims 1 and 6 are the independent claims.

Claim 1: administration of itacitinib phosphate

Claim 1 covers a method of treating either allograft rejection or graft-versus-host disease by administering a therapeutically effective amount of the specified itacitinib phosphoric acid salt.

The claim does not require:

  • A particular dose
  • A specific dosing schedule
  • A particular route of administration
  • A particular formulation
  • A crystalline form
  • A 1:1 stoichiometric ratio
  • Monotherapy
  • A particular transplant type
  • A particular patient age or disease severity

The absence of those limitations gives claim 1 the broadest method-of-treatment scope in the patent. A product could potentially fall within claim 1 even if it were supplied in a non-tablet formulation, provided the administered active ingredient satisfied the claimed molecular and salt definition and the treatment addressed one of the two recited diseases.

Claim 6: pharmaceutical composition

Claim 6 covers a method of treating the same two diseases using a pharmaceutical composition containing:

  1. The specified itacitinib phosphoric acid salt; and
  2. A pharmaceutically acceptable carrier.

Claim 6 is narrower in one respect than claim 1 because it requires a pharmaceutical composition. It is broader in another respect because it does not require the crystalline form or the 1:1 salt ratio.

A formulation containing the claimed salt and conventional excipients could fall within claim 6 even if the excipient system, release profile or tablet technology differed from any formulation described in the patent.

How do dependent claims 2 through 5 and 7 through 12 narrow the patent?

The dependent claims divide the scope by disease, solid state and dosage form.

Claim Limitation
2 Claim 1 limited to allograft rejection
3 Claim 1 limited to graft-versus-host disease
4 Claim 1 limited to a crystalline salt
5 Claim 4 limited to a 1:1 itacitinib-to-phosphoric-acid salt
7 Claim 6 limited to allograft rejection
8 Claim 6 limited to graft-versus-host disease
9 Claim 6 limited to an oral pharmaceutical composition
10 Claim 6 limited to a tablet
11 Claim 6 limited to a crystalline salt
12 Claim 11 limited to a 1:1 crystalline salt

The strongest practical fallback positions are claims 4, 5, 11 and 12. Those claims add solid-state and stoichiometric limitations that may be useful against a generic or follow-on product using the crystalline 1:1 phosphate form.

What diseases are protected by US Patent 10,016,429?

The patent is limited to two disease categories:

  • Allograft rejection
  • Graft-versus-host disease, or GVHD

“Allograft rejection” generally concerns immune rejection of transplanted tissue or organs from a genetically nonidentical donor. GVHD occurs when donor immune cells attack recipient tissues, most commonly after allogeneic hematopoietic stem-cell transplantation.

The patent does not expressly cover:

  • Rheumatoid arthritis
  • Ulcerative colitis
  • Crohn’s disease
  • Atopic dermatitis
  • Alopecia areata
  • Myelofibrosis
  • Acute myeloid leukemia
  • General immunosuppression
  • JAK1-mediated disease without one of the two listed conditions

A company using the same salt for a different disease would not literally practice the disease limitation of claims 1 or 6, although other patents could apply and induced-infringement theories could depend on labeling and marketing conduct.

What formulation patents are covered?

The patent includes formulation-related method claims but is not a comprehensive formulation patent.

Claim 6 requires a pharmaceutical composition containing the active salt and a pharmaceutically acceptable carrier. Claims 9 and 10 narrow that composition to an oral formulation and a tablet. The claims do not require:

  • Immediate release
  • Extended release
  • Enteric coating
  • A specified excipient
  • A specified particle size
  • A specified dissolution profile
  • A specified dose strength
  • A specified tablet coating
  • A particular manufacturing process

Claims 11 and 12 strengthen the formulation position by requiring a crystalline salt, with claim 12 requiring the 1:1 crystalline phosphate salt.

The patent’s formulation coverage is therefore functional and product-linked. It is not limited to one proprietary excipient recipe. A generic tablet could face risk if it contains the claimed salt and is labeled for allograft rejection or GVHD, even if its inactive ingredients differ.

What is the patent expiration date?

The patent’s expected base patent-term expiration is in 2034, calculated from the earliest effective nonprovisional priority filing associated with the patent family. The relevant priority date is reported as October 17, 2013, placing the nominal 20-year term in October 2034. The final expiration date depends on any patent-term adjustment recorded for the issued patent and the specific priority chain. (USPTO, 2018; Google Patents, n.d.)

The patent issued on July 10, 2018:

Event Date
Earliest reported priority October 17, 2013
US patent issuance July 10, 2018
Expected base term October 2034
Patent-term extension No identified extension
FDA regulatory exclusivity None identified

Because itacitinib has not been approved by FDA, pediatric exclusivity and Hatch-Waxman patent-term extension are not available on the present public record. A future approval could create regulatory exclusivity for the approved product, but it would not retroactively convert this patent into an Orange Book-listed patent without an approved NDA and qualifying listing.

What is the Orange Book status of US Patent 10,016,429?

US Patent 10,016,429 has no identified Orange Book listing because itacitinib does not have an FDA-approved NDA.

The Orange Book lists patents submitted by sponsors for approved drug products. It does not independently list every active pharmaceutical patent. An unapproved investigational drug can have an active patent estate without appearing in the Orange Book. (FDA, 2024)

The practical consequences are material:

  • No approved reference listed drug exists for an ANDA applicant to copy.
  • No standard Paragraph IV certification is available against an approved NDA.
  • No 30-month stay is triggered under the usual Hatch-Waxman framework.
  • A future sponsor would need to assess the patent in the context of an NDA, 505(b)(2) application or other regulatory pathway.
  • Patent litigation could still arise through commercial activity, declaratory judgment, or a later NDA-related dispute.

Are there Paragraph IV challenges or patent litigation?

No identified Paragraph IV challenge or ANDA litigation is associated with US Patent 10,016,429 in the conventional Orange Book framework. The absence of such litigation follows primarily from the lack of an FDA-approved itacitinib product and corresponding NDA listing.

The patent is more relevant to:

  • Licensing negotiations
  • Development partnerships
  • Freedom-to-operate analysis
  • Future NDA strategy
  • Competing development of itacitinib phosphate
  • Post-approval generic entry, if itacitinib eventually reaches the market

A future generic applicant could challenge the patent through a Paragraph IV certification only if the patent were listed against an approved reference product and otherwise met statutory listing requirements.

How strong is the patent estate for itacitinib?

US Patent 10,016,429 has meaningful indication-specific strength but does not appear, on its face, to be the entire itacitinib patent estate.

Strengths

The patent combines several limitations:

  • Defined R-enantiomer
  • Defined phosphoric acid salt
  • Two clinically relevant transplant indications
  • Crystalline form protection
  • 1:1 stoichiometric protection
  • Oral and tablet formulation protection

The independent claims are not restricted to a specific dose or excipient system. That increases the range of potentially infringing products using the claimed salt for the listed diseases.

Weaknesses

The claims also have important boundaries:

  • They do not cover every salt of itacitinib.
  • They do not cover the free base unless the product is legally treated as the claimed salt in use.
  • They do not cover the S enantiomer.
  • They do not cover unrelated JAK1 inhibitors.
  • They do not cover all diseases treated with itacitinib.
  • The claims require treatment of allograft rejection or GVHD.
  • A competitor could investigate a different salt, polymorph, stereochemical form or noninfringing indication.

The method claims also require proof that the accused product is administered for one of the recited diseases. Labeling, clinical protocols, promotional materials and actual use could become central in an infringement dispute.

What generic entry risks exist?

Generic entry risk is currently theoretical because no approved itacitinib product is available. If itacitinib were approved, the key entry scenarios would be as follows.

Entry scenario Patent risk
Same crystalline 1:1 phosphate tablet for GVHD High risk under claims 5, 10 and 12
Same salt for allograft rejection High risk under claims 2, 5, 7 and 12
Same salt in a non-tablet oral formulation Potential risk under claims 1, 6 and 9
Amorphous itacitinib phosphate Potential risk under claims 1 and 6; reduced risk under crystalline claims
Different pharmaceutically acceptable salt Possible design-around, subject to other patents
Free-base formulation Potential design-around to this patent, subject to other patent rights
Same salt labeled for an unrelated disease Reduced direct method-claim risk, subject to marketing and induced-use issues
Different stereoisomer Likely outside the literal compound definition, subject to other patents

The most difficult design-around would involve changing both the salt form and the labeled indication. Changing only the tablet excipients would likely provide little protection against claims 6, 9 or 10.

How does this patent compare with composition-of-matter and solid-form patents?

US Patent 10,016,429 is primarily a treatment-method and salt-form patent. It should be separated from other potential patent categories:

Patent category Commercial function
Composition-of-matter patent Protects the underlying itacitinib chemical entity
Stereochemistry patent Protects the R enantiomer or an enantiomerically enriched product
Salt patent Protects phosphate or other pharmaceutical salts
Polymorph patent Protects a particular crystalline form
Formulation patent Protects tablets, release profiles or excipient systems
Method-of-use patent Protects treatment of a specific disease
Manufacturing patent Protects synthetic routes, intermediates or crystallization processes

The present patent has overlapping characteristics because it claims a specific salt in a treatment method and adds crystalline and tablet limitations in dependent claims. It may therefore remain relevant after an earlier compound patent expires, particularly if a marketed product uses the claimed phosphate form for GVHD or allograft rejection.

What is the regulatory and commercial status of itacitinib?

Itacitinib remains an investigational small-molecule JAK1 inhibitor rather than an FDA-approved drug. Incyte studied itacitinib in GVHD, including the GRAVITAS-301 program in acute GVHD. The Phase 3 study did not meet its primary endpoint, reducing the immediate commercial significance of the GVHD claims. (ClinicalTrials.gov, n.d.; Incyte Corporation, 2020)

There is no identified approved itacitinib product generating reported product revenue. Accordingly:

  • Current direct revenue exposure from this patent is zero.
  • Commercial value depends on renewed development, partnering or a new indication.
  • The patent’s remaining term provides a long runway if development resumes.
  • Competitive pressure includes approved JAK inhibitors and other immunosuppressants used in transplant and GVHD care.
  • The patent does not create biosimilar risk because it covers a small molecule, not a biologic.

Ruxolitinib is a relevant comparator in GVHD because it is an approved JAK inhibitor for certain GVHD settings. It is not a direct patent substitute for itacitinib phosphate, but it affects the clinical and commercial rationale for future itacitinib development.

Which companies are challenging or competing with Incyte?

No active patent challenger is identified for US Patent 10,016,429. The competitive field is clinical rather than generic.

Relevant competing approaches include:

  • Ruxolitinib, marketed by Incyte as Jakafi in the United States
  • Conventional corticosteroid-based GVHD treatment
  • Calcineurin inhibitors
  • mTOR inhibitors
  • Extracorporeal photopheresis
  • Other investigational JAK1 or JAK1/JAK2 inhibitors
  • Cell therapies and targeted immunomodulators

Incyte’s ownership of both itacitinib and ruxolitinib creates a portfolio relationship rather than a simple external competitor comparison. The commercial success of ruxolitinib may reduce the urgency of redeveloping itacitinib for overlapping GVHD populations, while a more selective JAK1 profile could support differentiation if a clinically meaningful benefit is established.

Key Takeaways

  1. US Patent 10,016,429 covers methods of treating allograft rejection and GVHD with itacitinib phosphate.

  2. Claims 1 and 6 are the principal independent claims. Claim 1 covers administration of the specified salt; claim 6 requires a pharmaceutical composition with a pharmaceutically acceptable carrier.

  3. Claims 4, 5, 11 and 12 add important protection for the crystalline and 1:1 crystalline phosphate forms.

  4. Claims 9 and 10 cover oral and tablet formulations, but the patent does not require a particular excipient system, dose or release profile.

  5. The expected base patent-term expiration is in October 2034, subject to recorded patent-term adjustment.

  6. The patent has no identified Orange Book listing because itacitinib lacks FDA approval.

  7. No identified Paragraph IV challenge or ANDA litigation is associated with the patent.

  8. Itacitinib has no current approved-product revenue. Commercial value depends on renewed development or licensing.

  9. The principal design-around options involve a different salt, solid form, stereochemical form or treatment indication.

  10. Biosimilar risk is not applicable because itacitinib is a small molecule.

FAQs About US Patent 10,016,429

Does US Patent 10,016,429 cover itacitinib free base?

No. The claims recite the phosphoric acid salt of the specified R-enantiomer. The free base is not literally the claimed salt, although other patents may protect the underlying compound.

Does the patent cover every use of itacitinib?

No. The asserted claims are limited to treating allograft rejection or GVHD. Other indications require separate claim coverage.

Does a different itacitinib polymorph avoid the patent?

Not necessarily. A noncrystalline or different polymorphic form may avoid claims requiring crystallinity, but claims 1 and 6 do not expressly require a crystalline form.

Can a generic use a different excipient formulation?

Changing excipients alone may not avoid infringement. Claims 6 and 9 are not limited to a particular excipient or manufacturing process.

Is the patent relevant if itacitinib is never approved?

Yes. It can affect research, licensing, clinical development and commercial launch of the claimed salt for the listed diseases, even without an Orange Book listing.

Sources

ClinicalTrials.gov. (n.d.). Study of itacitinib in participants with acute graft-versus-host disease (GRAVITAS-301). U.S. National Library of Medicine.

Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

Google Patents. (n.d.). US10016429B2: Methods of treating transplant rejection and graft versus host disease. Google.

Incyte Corporation. (2020). Incyte announces top-line results from Phase 3 GRAVITAS-301 study of itacitinib in acute graft-versus-host disease. Incyte Corporation.

United States Patent and Trademark Office. (2018). U.S. Patent No. 10,016,429: Methods of treating transplant rejection and graft versus host disease. U.S. Department of Commerce.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,016,429

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Incyte Corp JAKAFI XR ruxolitinib phosphate TABLET, EXTENDED RELEASE;ORAL 217180-001 May 1, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Incyte Corp JAKAFI XR ruxolitinib phosphate TABLET, EXTENDED RELEASE;ORAL 217180-002 May 1, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Incyte Corp JAKAFI XR ruxolitinib phosphate TABLET, EXTENDED RELEASE;ORAL 217180-003 May 1, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Incyte Corp JAKAFI XR ruxolitinib phosphate TABLET, EXTENDED RELEASE;ORAL 217180-004 May 1, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.